hackint0sh/New-Dataset huggingface dataset:
To evaluate the efficacy of the initial treatment with SVF IV. conditions: Pulmonary Fibrosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ACTUAL name: Autologous adipose-derived SVF IV administration measure: Safety of treatment with SVF IV measure: Efficacy of the initial treatment with SVF IV measure: Effectiveness of the initial treatment with SVF IV sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Escuela Oscar Danilo Rosales Arguello (HEODRA) city: León state: Leon zip: 21000 country: Nicaragua lat: 12.43787 lon: -86.87804 facility: Hospital Escuela Cesar Amador Molina city: Matagalpa zip: 61000 country: Nicaragua lat: 12.92559 lon: -85.91747 hasResults: False
nctId: NCT06304610 id: ONZ-2024-0044 briefTitle: Hospital-based Validation of the New ELEVATE Screening Tool in Belgium and Ecuador acronym: ELEVATE-Pilot overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-12 date: 2024-03-28 name: University Hospital, Ghent class: OTHER name: Horizon 2020 - European Commission name: Universidad de Cuenca briefSummary: ELEVATE is a six-year project, conducted by an international research alliance led by Ghent University, aiming to develop a new test and approach for cervical cancer screening in hard-to-reach populations.
At each study site, 100 women between 30-65 years old, with a recent abnormal pap smear result will be recruited in the colposcopy waiting room. After registration and signing the informed consent form, each woman will be asked to fill out a short self-administered questionnaire for socio-demographic information. Each woman will provide a self-sample as well as an endocervical sample before the colposcopy examination. Both samples of all 200 women (i.e. participants from Belgium and Ecuador) will be tested with the new ELEVATE screening test, using 400 ELEVATE cartridges, as well as with standard tests.
Concordance between the test results of the ELEVATE screening test and standard lab tests on both type of samples will be defined, for HPV DNA as well as protein detection. Additionally, the sensitivity and specificity of the HPV DNA test and the protein test of the ELEVATE screening test will be defined, according to clinically relevant outcomes. conditions: Cervical Cancer conditions: HPV Infection studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: all participants receive the same tests primaryPurpose: PREVENTION masking: NONE count: 200 type: ESTIMATED name: Questionnaire name: HPV self-sample name: Endocervical sample measure: Clinical validation measure: Concordance measure: HPV DNA test validation measure: Protein test validation sex: FEMALE minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ghent University Hospital city: Ghent state: East-Flanders zip: 9000 country: Belgium name: Steven Weyers, MD,PhD,Prof role: CONTACT phone: 09 332 37 83 email: steven.weyers@uzgent.be name: Philippe Tummers, MD,PhD,Prof role: CONTACT phone: 09 332 37 83 email: philippe.tummers@uzgent.be name: Philippe Tummers, MD,PhD,Prof role: PRINCIPAL_INVESTIGATOR name: Heleen Vermandere, PhD role: SUB_INVESTIGATOR name: Marie Hendrickx, MSC role: SUB_INVESTIGATOR lat: 51.05 lon: 3.71667 facility: SOLCA University Hospital city: Cuenca country: Ecuador name: Bernardo José Vega Crespo role: CONTACT phone: 0998276441 email: bernardo.vegac@ucuenca.edu.ec name: Bernardo José Vega Crespo role: PRINCIPAL_INVESTIGATOR name: Dayanara Delgado role: SUB_INVESTIGATOR name: Vivian Alejandra Neira Molina role: SUB_INVESTIGATOR lat: -2.90055 lon: -79.00453 hasResults: False
nctId: NCT06304584 id: P-2023-143 briefTitle: Cross-sectoral Rehabilitation of Older High-risk Patients With Hip Fracture overallStatus: RECRUITING date: 2023-05-15 date: 2024-09-15 date: 2025-05-15 date: 2024-03-12 date: 2024-03-12 name: University Hospital Bispebjerg and Frederiksberg class: OTHER name: Frederiksberg Municipality briefSummary: The goal of this observational study is to learn about and monitor the cross-sectoral rehabilitation process in older high-risk patients treated for at fragility fracture of the hip.
Participants age 65 and above with home address in Frederiksberg municipality, living in own home, admitted and treated for at hip fracture at Department of Orthopedic Surgery, Bispebjerg Hospital, will be asked for participation. conditions: Hip Fractures conditions: Rehabilitation conditions: Recovery of Function studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ESTIMATED measure: Recovery of pre-fracture function measure: Basic mobility measure: 30 second chair stand test (CST) measure: Timed Up & Go test (TUG) measure: Hip related pain measure: Hand Grip Strength (HGS) measure: Health questionnaire measure: Physical activity (weekly) measure: Physical activity / upright time (time standing and walking) measure: Frailty measure: Fear of falling measure: Comorbidity measure: Cognitive status measure: Number of falls measure: Residential status / discharge destination measure: Length of stay in acute hospital measure: Number of weekly exercise sessions with therapist in all settings measure: Number of rehab weeks measure: Type of training in Municipality measure: Training after discharge from 24-hour setting measure: Home care, nurse/other health assistance, times pr week measure: Data 30 days post-discharge measure: Data 3 months post-discharge measure: Data 1 year post-discharge sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Department of Physio- and Occupational Therapy and Othopedic Surgery, University Hospital Bispebjerg and Frederiksberg status: RECRUITING city: Copenhagen zip: 2400 country: Denmark name: Morten T Kristensen, Professor role: CONTACT email: morten.tange.kristensen@regionh.dk name: Camilla K Zilmer, MSc, PT role: CONTACT email: camilla.kampp.zilmer@regionh.dk lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06304571 id: HC006-001 briefTitle: A Study of HC006 in Subjects With Advanced Solid Tumors overallStatus: RECRUITING date: 2024-02-27 date: 2026-03-15 date: 2026-07-16 date: 2024-03-12 date: 2024-03-12 name: HC Biopharma Inc. class: INDUSTRY briefSummary: The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid tumor malignancies. This study is a first-in-human (FIH) study of HC006 in subjects with advanced solid tumors. conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 76 type: ESTIMATED name: HC006 measure: Incidence of Dose Limiting Toxicities(DLTs) measure: Incidence of adverse events(AEs) measure: Incidence of Serious adverse events(SAEs) measure: Clinically Significant changes in safety assessments measure: Pharmacokinetic (PK) Parameter:Maximum serum concentration (Cmax) measure: PK Parameter:Time to reach Cmax (Tmax) measure: PK Parameter:Area Under the Concentration-time Curve (AUC) measure: Immunogenicity measure: Objective Response Rate (ORR) per RECIST 1.1 measure: progression-Free Survival (PFS) per RECIST 1.1 measure: Overall Survival (OS) measure: Disease Control Rate (DCR) per RECIST 1.1 measure: Duration of response (DOR) per RECIST 1.1 measure: Time to progression (TTP) per RECIST 1.1 measure: Time To Response (TTR) per RECIST 1.1 sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai East Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200120 country: China name: Ye Guo, MD role: CONTACT email: pattrickguo@gmail.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06304558 id: CI 240228, 2024-480 briefTitle: "Effectiveness of Non-invasive Neuromodulation Treatment for Improving Sexual Satisfaction in Healthy Subjects. overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2024-04 date: 2024-06 date: 2024-03-12 date: 2024-03-12 name: Universidad Europea de Madrid class: OTHER briefSummary: The main objectives of the programming with the XSignal device will be to influence the sexual satisfaction of the participants.
As secondary objectives, the effectiveness of the XSignal device during a defined treatment period will be analyzed in terms of quality of life, pain, stress, anxiety, sexual function, sleep quality, cortisol, heart rate, blood pressure, respiratory rate, and body temperature of the same subjects, compared with a placebo group, observing the long-term influence of the results. conditions: Sexual Satisfaction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The Placebo group will mimic the Intervention group, but the device will not be connected. With this non-invasive neuromodulation, patiens do not experiment any sensation when the device is connected. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Non-Invasive Neuromodulation (NESA) measure: Sexual satisfaction measure: Stress levels measure: Blood Pressure (Sistolic and diastolic) measure: Heartbeats per minute measure: Sleep Quality sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304545 id: SHR-1210-HLJ-081 briefTitle: Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-08-16 date: 2027-03-15 date: 2024-03-12 date: 2024-03-12 name: Harbin Medical University class: OTHER briefSummary: This is a single-arm, phase II clinical study aim to evaluate the efficacy and safety of long-term concurrent chemoradiotherapy combined with camrelizumab as a neoadjuvant therapy in the treatment of locally advanced/low rectal cancer requiring anus preservation. conditions: Rectal Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 48 type: ESTIMATED name: Camrelizumab name: Chemotherapy name: Radiotherapy measure: Pathological Complete Response rate measure: Objective Response Rate measure: Disease Control Rate measure: Anal preservation rate measure: Disease-free Survival measure: Overall Survival measure: AEs measure: 3-years Overall Survival rate sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06304532 id: HU123 briefTitle: Clinical Efficacy and Safety Assessment of Alsareen Capsule for the Management of H. Pylori Infection overallStatus: COMPLETED date: 2023-08-15 date: 2024-03-05 date: 2024-03-06 date: 2024-03-12 date: 2024-03-13 name: Hamdard University class: OTHER briefSummary: Helicobacter pylori infection is a major cause of morbidity and mortality worldwide. More than 50% of the global population is estimated to be infected. In 2015, there were approximately 4.4 billion individuals with H pylori infection worldwide. In Pakistan the prevalence of H. pylori infection, highest (63%) in middle age (41-60 years) group while lowest (33%) in teens and pre-teens (\<20 years) group. In young age (20-40) and old age (\>60 years) groups, the prevalence of H. pylori was 55% and 60% respectively.
In conventional system of medicine H. pylori infection is treated by triple regimen antibiotic therapy that are amoxicillin, clarithromycin and metronidazole along with acid reducing proton pump inhibitor. Due to recurrence of infection this therapy is repeated multiple times resulting in drug resistance and long term side effects. These side effects \& a long term impact of H. pylori in patient general health necessitates development of a safe and long term effective therapy. conditions: H. Pylori Infection studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 69 type: ACTUAL measure: H. pylori stool for antigen test will screened before and after treatment. sex: ALL minimumAge: 15 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT facility: Shifa Ul Memorial Hospital-Hamdard University city: Karachi state: Sindh country: Pakistan lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06304519 id: 1986626-1 briefTitle: Identifying the Optimal Dynamic Ankle-Foot Orthosis Bending Stiffness for Individuals Post-Stroke overallStatus: RECRUITING date: 2023-03-01 date: 2026-02-28 date: 2026-02-28 date: 2024-03-12 date: 2024-03-12 name: University of Delaware class: OTHER briefSummary: Ankle braces are commonly prescribed to individuals who have suffered a stroke to help their ankle joints work properly, which allows these individuals to walk better. Currently, there are no standardized guidelines to follow when choosing which brace is best for an individual. Prior work has shown that customizing the level of assistance that these braces provide based on each individual's level of ankle impairment improves the individuals' walking function more than their current brace. The next important step is to fine-tune the customization and work to develop a set of guidelines that can be used by clinicians to help them prescribe the right brace for each patient's needs. The purpose of this study is to test different levels of assistance provided by the brace to determine the optimal customization method. Additionally, this study aims to begin to create a guide to help clinicians choose the best brace for each individuals' needs. To accomplish this goal, individuals will walk with a brace under five different assistance level conditions. The individual's walking function, performance on clinical measures, and response to questionnaires will be examined to determine both the optimal brace for each individual and hopefully identify clinical tools that can be used to guide prescription of the brace. This study is a major step towards developing effective, standardized prescription guidelines that optimize walking of individuals post-stroke. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: Dynamic ankle-foot orthosis measure: Mechanical Cost of Transport of the Lower Extremities measure: Sagittal plane ankle moment during stance measure: Sagittal plane ankle angle during stance measure: Self-selected walking speed measure: a candidate set of clinical outcome measures sex: ALL minimumAge: 21 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Delaware STAR Campus status: RECRUITING city: Newark state: Delaware zip: 19713 country: United States name: Elisa Arch, Ph.D. role: CONTACT phone: 302-831-7268 email: schranke@udel.edu lat: 39.68372 lon: -75.74966 hasResults: False
nctId: NCT06304506 id: 514-0894/23-3000 briefTitle: Effect of Obesity on Extracellular Matrix Composition acronym: EOBECM overallStatus: RECRUITING date: 2024-03-15 date: 2024-11-15 date: 2024-12-30 date: 2024-03-12 date: 2024-03-12 name: University of Copenhagen class: OTHER briefSummary: The experiment is a simple cross-sectional study with three groups (n=10) in each group, young and old healthy men and obese young men. The study will investigate the composition of the adipose tissue extra cellular matrix.
- is there differences in the adipose tissue extracellular matrix in obese compared to young men is there differences in the adipose tissue extracellular matrix in old compared to young men conditions: Adipose Tissue studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Cross sectional study with three groups primaryPurpose: BASIC_SCIENCE masking: NONE count: 30 type: ESTIMATED name: Cross sectional study measure: The effect of obesity and age on adipose tissue extracellular matrix composition sex: MALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xlab, Faculty of Health and Medical Sciences, University of Copenhagen status: RECRUITING city: Copenhagen zip: 2200 country: Denmark name: Jørn M Helge, PhD role: CONTACT phone: +4528757506 email: jhelge@sund.ku.dk lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06304493 id: 23-2470 briefTitle: REMINDers for Incentive Spirometry in PACU (REMIND-IS in PACU) overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-05 date: 2024-05 date: 2024-03-12 date: 2024-03-12 name: University of Colorado, Denver class: OTHER briefSummary: The purpose of this study is to determine if the frequency of use of incentive spirometry during the stay in the Post-Anesthesia Care Unit (PACU) increases with visual and auditory electronic reminders, as compared to not having those reminders. conditions: Postoperative Atelectasis conditions: Postoperative Hypoxemia conditions: Postoperative Pneumonia conditions: Postoperative Pulmonary Complications conditions: Patient Adherence conditions: Incentive Spirometry conditions: Respiratory Therapy conditions: Respiratory Insufficiency studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a pragmatic single-center cluster study of surgical patients receiving incentive spirometry devices during their PACU stay, with either automatic alarms "ON" or "OFF" in alternating weeks. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Outcome collection and data analysis will be performed by investigators blinded to the patient's cluster allocation (alarms "ON" or "OFF"). whoMasked: OUTCOMES_ASSESSOR count: 300 type: ESTIMATED name: Alarms measure: Rate of adequate IS breaths achieved in PACU measure: Rate of IS breaths attempted in PACU measure: Time to first adequate IS breath measure: Duration of postoperative O2 therapy measure: Presence of postoperative pulmonary complications measure: Individual postoperative pulmonary complications measure: Need for ICU Admission after PACU measure: PACU Length of Stay sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CU Anschutz city: Aurora state: Colorado zip: 80045 country: United States name: Emily G Helmer role: CONTACT phone: 303-724-2938 email: emily.helmer@cuanschutz.edu name: Carolyn Gronowski role: CONTACT email: carolyn.gronowski@cuanschutz.edu name: Ana Fernandez-Bustamante, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06304480 id: AFCRO-179 briefTitle: Effect of The Substitution of Animal Protein by Soya-Based Fermented Product on Human Gut Microbiome overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-07-31 date: 2024-07-31 date: 2024-03-12 date: 2024-03-12 name: University College Cork class: OTHER name: AIT Austrian Institute of Technology GmbH briefSummary: There is a growing understanding of the functioning and interconnectedness of microbiomes in the food system which offers great potential for enabling the development of new solutions contributing to achieving important food and nutrition goals including those requested by FOOD 2030. Of relevance in this regard is the provision of sustainable and healthy protein sources. Because of the obvious environmental and climate concerns associated with the production of animal-derived protein, a transition is needed to healthier and more environment-friendly diets, including a moderate-level consumption of red and processed meat and greater emphasis on plant-based foods.
As well as impact of meat production on the climate, it is well established that eating a diet rich in red meat promotes the growth of gut microbiome members that drive or exacerbate inflammation. Plant protein does not have these associations, and in fact it is often accompanied by fibre ingestion, which favours growth of health-promoting gut microbes. Replacing meat with plant protein offers the prospect of improving consumer health by improving the gut microbiome. The EU funded project MICROBIOMES4SOY will assess the effect of replacing animal protein with soya-derived protein on the human gut microbiome and whether this replacement can reduce the risk of inflammation-related diseases by gut microbiome modulation. This knowledge will provide a baseline for establishing new dietary pathways making use of soya protein and support dietary transition for EU citizens. conditions: Gut Microbiome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised, open label, controlled, parallel study in healthy males and females. primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: Randomised, open label, controlled, parallel study in healthy males and females. count: 50 type: ESTIMATED name: 100g fermented Tofu measure: To evaluate the effect of replacing animal protein in a typical Western diet with plant-derived protein delivered in a (soy-based) tofu on gut microbiome composition. measure: To evaluate the functional activity of the gut microbiome, and any alterations caused by the soya replacement. measure: To evaluate the metabolome of urine and faecal samples and any alterations caused by the soya replacement. measure: To measure the effect of the meat substitution on a panel of proinflammatory cytokines, based on the observation that particular taxa are associated with an inflammatory phenotype. measure: To measure the effect of the meat substitution on cholesterol and serum triglycerides. measure: To measure the effect of the meat substitution on blood pressure. measure: To measure the effect of the meat substitution on body mass index (BMI). sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06304467 id: IRB#23-001133 briefTitle: CM for Patients With ALD After Liver Transplant overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-09-01 date: 2026-03-01 date: 2024-03-12 date: 2024-03-12 name: Arpan A. Patel, MD class: OTHER briefSummary: Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S. and is now the leading cause of cirrhosis-related hospitalizations, cirrhosis- related deaths, and liver transplantation. Alcohol use disorder (AUD), the root cause of ALD, affects 15 million Americans each year. While research studies have shown that behavioral therapy and medications specific for alcohol use have helped people overcome their alcohol use disorder, there has not been enough information related to how successful these treatments are specifically for people with ALD. This study will look at a behavioral treatment called "contingency management" (CM) that has shown to be effective with people with other substance use disorders. CM is based on the principles of operant conditioning that involves offering prize-based or monetary incentives to patients with substance use disorders to reduce substance use. This study will look at the efficacy and acceptability of CM in patients who received a liver transplant and have evidence of recurrent alcohol use.